What is ARCALYST® (rilonacept) and what condition is it being studied for?

ARCALYST® (rilonacept) is a drug developed by Regeneron Pharmaceuticals, Inc. This 8-K filing specifically addresses its evaluation in two Phase 3 clinical studies for the treatment of gout, a type of inflammatory arthritis.

What is the significance of the Phase 3 study results announced?

Phase 3 study results are a crucial step in the drug development process. Positive results indicate that the drug is likely effective and safe for its intended use, and they are a prerequisite for seeking regulatory approval from agencies like the FDA. For investors, these results directly impact the future commercial potential and valuation of Regeneron.

Where can I find more details about the Phase 3 study results?

The detailed results are available in the press release dated June 9, 2010, which is included as Exhibit 99(a) to this 8-K filing. Additionally, presentation slides from the webcast where management discussed these findings are available as Exhibit 99(b).

What are the 'two different gout settings' mentioned in the filing?

While the filing itself doesn't specify the exact nature of the 'two different gout settings,' this detail would typically refer to distinct patient populations or treatment regimens within the gout indication being investigated in the Phase 3 trials. Investors would need to refer to the press release (Exhibit 99(a)) or webcast slides (Exhibit 99(b)) for specific details on these settings.

REGN 8-K SEC Disclosure

Summary

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on June 10, 2010, to announce the results of two Phase 3 clinical studies for its drug ARCALYST® (rilonacept) concerning its efficacy and safety in two distinct gout treatment settings. The company has provided a press release detailing these findings as an exhibit, along with presentation slides from a webcast hosted by senior management to discuss these important study outcomes. These Phase 3 results are critical for investors as they represent a significant milestone in the development and potential commercialization of ARCALYST® for gout. Positive outcomes could pave the way for regulatory approval and future revenue streams, while any adverse findings or uncertainties could impact the stock's valuation. The webcast and accompanying slides offer direct insight into management's perspective on the data and the drug's prospects.

Key Highlights

1Regeneron announced positive results from two Phase 3 studies of ARCALYST® (rilonacept) for gout.
2The reported results focus on the efficacy and safety of ARCALYST® in two different gout-related settings.
3A press release detailing these Phase 3 study results was issued on June 9, 2010.
4Regeneron's CEO and senior management hosted a webcast to discuss the study findings.
5Presentation slides from the webcast are furnished as an exhibit to the 8-K filing.
6This filing is significant as it provides key clinical development updates for ARCALYST®.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Jun 10, 2010)

Summary

Key Highlights

Frequently Asked Questions